Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply ...
Eli Lilly (LLY) is exiting CVS Health’s (CVS) drug benefit plan for its employees after the managed care giant decided to limit access to the company’s popular weight loss drug, Zepbound, in favor of ...
Here are four recent updates from CVS Health: 1. CVS Health subsidiary Omnicare has filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the Northern District of Texas. The filing follows ...
As evidence grows supporting the potential health benefits of obesity drugs like Novo Nordisk’s Wegovy and Eli Lilly & Co.’s Zepbound, so too — frustratingly — do the barriers to accessing them. The ...
A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli Lilly’s blockbuster weight-loss drug. CVS Caremark stopped covering Zepbound ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback